ash, cash equivalents and marketable securities will be at least $125 million at the end of 2013, inclusive of research funding from Shire but exclusive of funds arising from any additional new collaborations or partnerships, or other new sources.
The Company reiterates its earlier guidance as follows:
Revenues: Sangamo expects that revenues will be in the range of $20 to $24 million in 2013, inclusive of research funding from Shire.
Operating Expenses: Sangamo expects that operating expenses will be in the range of $46 to $50 million for 2013.
Conference CallSangamo will host a conference call today, Wednesday, October 23, 2013, at 5:00 p.m. ET, which will be open to the public. The call will also be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Events and Presentations" http://investor.sangamo.com/events.cfm. A replay of the webcast will also be available for two weeks after the call. During the conference call, the company will review these results, discuss other business matters, and provide guidance with respect to the rest of 2013.
The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 79054132. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on October 23, 2013 to 11:59 p.m. ET on October 30, 2013. The conference call replay numbers for domestic and international callers are 855-859-2056 and 404-537-3406, respectively. The conference ID number for the replay is 79054132.
About SangamoSangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Co
Page: 1 2 3 4 5 6 7 8 Related biology technology :1
|SOURCE Sangamo BioSciences, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option2
. Sangamo BioSciences Proposes Public Offering Of Common Stock3
. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL4
. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference5
. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference6
. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference7
. Sangamo BioSciences Announces Presentation At Regen Med Investor Day8
. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast9
. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference10
. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference11
. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast